Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256

1.

Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study.

Sgadari C, Monini P, Tripiciano A, Picconi O, Casabianca A, Orlandi C, Moretti S, Francavilla V, Arancio A, Paniccia G, Campagna M, Bellino S, Meschiari M, Nozza S, Sighinolfi L, Latini A, Muscatello A, Saracino A, Di Pietro M, Galli M, Cafaro A, Magnani M, Ensoli F, Ensoli B.

Front Immunol. 2019 Feb 13;10:233. doi: 10.3389/fimmu.2019.00233. eCollection 2019.

2.

Genetic diversity in the env V1-V2 region of proviral quasispecies from long-term controller MHC-typed cynomolgus macaques infected with SHIVSF162P4cy.

Capone A, Lo Presti A, Sernicola L, Farcomeni S, Ferrantelli F, Maggiorella MT, Mee ET, Rose NJ, Cella E, Ciccozzi M, Ensoli B, Borsetti A.

J Gen Virol. 2018 Dec;99(12):1717-1728. doi: 10.1099/jgv.0.001159. Epub 2018 Oct 12.

PMID:
30311877
3.
4.

The HIV-1 Tat protein affects human CD4+ T-cell programing and activation, and favors the differentiation of naïve CD4+ T cells.

Nicoli F, Gallerani E, Sforza F, Finessi V, Chachage M, Geldmacher C, Cafaro A, Ensoli B, Caputo A, Gavioli R.

AIDS. 2018 Mar 13;32(5):575-581. doi: 10.1097/QAD.0000000000001734.

PMID:
29280760
5.

"cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies".

Cafaro A, Sgadari C, Picconi O, Tripiciano A, Moretti S, Francavilla V, Pavone Cossut MR, Buttò S, Cozzone G, Ensoli F, Monini P, Ensoli B.

Expert Rev Vaccines. 2018 Feb;17(2):115-126. doi: 10.1080/14760584.2018.1418666. Epub 2017 Dec 22. Review.

PMID:
29243498
6.

Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells.

Bacigalupo I, Palladino C, Leone P, Toschi E, Sgadari C, Ensoli B, Barillari G.

Oncol Lett. 2017 May;13(5):2903-2908. doi: 10.3892/ol.2017.5835. Epub 2017 Mar 9.

7.

Correlates of infection and molecular characterization of blood-borne HIV, HCV, and HBV infections in HIV-1 infected inmates in Italy: An observational cross-sectional study.

Sanarico N, D'Amato S, Bruni R, Rovetto C, Salvi E, Di Zeo P, Chionne P, Madonna E, Pisani G, Costantino A, Equestre M, Tosti ME, Cenci A, Maggiorella MT, Sernicola L, Pontali E, Pansera A, Quattrocchi R, Carbonara S, Signorile F, Surace LA, Federzoni G, Garlassi E, Starnini G, Monarca R, Babudieri S, Rapicetta M, Pompa MG, Caraglia A, Ensoli B, Ciccaglione AR, Buttò S.

Medicine (Baltimore). 2016 Nov;95(44):e5257.

8.

Entrance of the Tat protein of HIV-1 into human uterine cervical carcinoma cells causes upregulation of HPV-E6 expression and a decrease in p53 protein levels.

Barillari G, Palladino C, Bacigalupo I, Leone P, Falchi M, Ensoli B.

Oncol Lett. 2016 Oct;12(4):2389-2394. Epub 2016 Jul 29.

9.

HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology.

Cafaro A, Piccaro G, Altavilla G, Gigantino V, Matarese G, Olivieri E, Ferrantelli F, Ensoli B, Palma C.

BMC Infect Dis. 2016 Aug 22;16(1):442. doi: 10.1186/s12879-016-1724-7.

10.

Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort.

Nicoli F, Chachage M, Clowes P, Bauer A, Kowour D, Ensoli B, Cafaro A, Maboko L, Hoelscher M, Gavioli R, Saathoff E, Geldmacher C.

BMC Infect Dis. 2016 Jul 22;16:344. doi: 10.1186/s12879-016-1647-3.

11.

HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.

Ensoli B, Nchabeleng M, Ensoli F, Tripiciano A, Bellino S, Picconi O, Sgadari C, Longo O, Tavoschi L, Joffe D, Cafaro A, Francavilla V, Moretti S, Pavone Cossut MR, Collacchi B, Arancio A, Paniccia G, Casabianca A, Magnani M, Buttò S, Levendal E, Ndimande JV, Asia B, Pillay Y, Garaci E, Monini P; SMU-MeCRU study group.

Retrovirology. 2016 Jun 9;13(1):34. doi: 10.1186/s12977-016-0261-1.

12.

Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection.

Nicoli F, Gallerani E, Skarlis C, Sicurella M, Cafaro A, Ensoli B, Caputo A, Marconi PC, Gavioli R.

Vaccine. 2016 Apr 27;34(19):2216-24. doi: 10.1016/j.vaccine.2016.03.022. Epub 2016 Mar 19.

PMID:
27002499
13.

Approaches to preventative and therapeutic HIV vaccines.

Gray GE, Laher F, Lazarus E, Ensoli B, Corey L.

Curr Opin Virol. 2016 Apr;17:104-109. doi: 10.1016/j.coviro.2016.02.010. Epub 2016 Mar 15. Review.

14.

Building up a collaborative network for the surveillance of HIV genetic diversity in Italy. A pilot study.

Sanarico N, D'Amato S, Picconi O, Ensoli B, Buttò S; Italian Network for HIV Characterization.

Ann Ist Super Sanita. 2015;51(4):321-6. doi: 10.4415/ANN_15_04_12.

15.

Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.

Cafaro A, Tripiciano A, Sgadari C, Bellino S, Picconi O, Longo O, Francavilla V, Buttò S, Titti F, Monini P, Ensoli F, Ensoli B.

Expert Opin Biol Ther. 2015;15 Suppl 1:S13-29. doi: 10.1517/14712598.2015.1021328. Epub 2015 Jun 22. Review.

PMID:
26096836
16.

HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.

Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, Lazzarin A, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, Ensoli B.

Retrovirology. 2015 Apr 29;12:33. doi: 10.1186/s12977-015-0151-y.

17.

Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide.

Finessi V, Nicoli F, Gallerani E, Sforza F, Sicurella M, Cafaro A, Caputo A, Ensoli B, Gavioli R.

Hum Vaccin Immunother. 2015;11(6):1489-93. doi: 10.1080/21645515.2015.1016676.

18.

Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines.

Titti F, Maggiorella MT, Ferrantelli F, Sernicola L, Bellino S, Collacchi B, Fanales Belasio E, Moretti S, Pavone Cossut MR, Belli R, Olivieri E, Farcomeni S, Compagnoni D, Michelini Z, Sabbatucci M, Sparnacci K, Tondelli L, Laus M, Cafaro A, Caputo A, Ensoli B.

PLoS One. 2014 Oct 30;9(10):e111360. doi: 10.1371/journal.pone.0111360. eCollection 2014.

19.

Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner.

Chiozzini C, Collacchi B, Nappi F, Bauer T, Arenaccio C, Tripiciano A, Longo O, Ensoli F, Cafaro A, Ensoli B, Federico M.

AIDS. 2014 Sep 24;28(15):2189-200. doi: 10.1097/QAD.0000000000000389.

PMID:
25313583
20.

Challenges in HIV Vaccine Research for Treatment and Prevention.

Ensoli B, Cafaro A, Monini P, Marcotullio S, Ensoli F.

Front Immunol. 2014 Sep 8;5:417. doi: 10.3389/fimmu.2014.00417. eCollection 2014. Review.

21.

An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge.

Sicurella M, Nicoli F, Gallerani E, Volpi I, Berto E, Finessi V, Destro F, Manservigi R, Cafaro A, Ensoli B, Caputo A, Gavioli R, Marconi PC.

PLoS One. 2014 Jul 17;9(7):e100844. doi: 10.1371/journal.pone.0100844. eCollection 2014.

22.

The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.

Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, Lazzarin A, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta F, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, Ensoli B.

Retrovirology. 2014 Jun 24;11:49. doi: 10.1186/1742-4690-11-49.

23.

Induction of antibodies and T cell responses by a recombinant influenza virus carrying an HIV-1 TatΔ51-59 protein in mice.

Garulli B, Di Mario G, Stillitano MG, Compagnoni D, Titti F, Cafaro A, Ensoli B, Kawaoka Y, Castrucci MR.

Biomed Res Int. 2014;2014:904038. doi: 10.1155/2014/904038. Epub 2014 May 14.

24.

HIV-1 Tat affects the programming and functionality of human CD8⁺ T cells by modulating the expression of T-box transcription factors.

Sforza F, Nicoli F, Gallerani E, Finessi V, Reali E, Cafaro A, Caputo A, Ensoli B, Gavioli R.

AIDS. 2014 Jul 31;28(12):1729-38. doi: 10.1097/QAD.0000000000000315.

PMID:
24841128
25.

Molecular characterization of HIV-1 subtype C gp-120 regions potentially involved in virus adaptive mechanisms.

Cenci A, D'Avenio G, Tavoschi L, Chiappi M, Becattini S, Narino Mdel P, Picconi O, Bernasconi D, Fanales-Belasio E, Vardas E, Sukati H, Lo Presti A, Ciccozzi M, Monini P, Ensoli B, Grigioni M, Buttò S.

PLoS One. 2014 Apr 30;9(4):e95183. doi: 10.1371/journal.pone.0095183. eCollection 2014.

26.

The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells.

Barillari G, Iovane A, Bacigalupo I, Labbaye C, Chiozzini C, Sernicola L, Quaranta MT, Falchi M, Sgadari C, Ensoli B.

Angiogenesis. 2014 Oct;17(4):831-8. doi: 10.1007/s10456-014-9430-9. Epub 2014 Apr 10.

PMID:
24719186
27.

Effect of MHC haplotype on immune response upon experimental SHIVSF162P4cy infection of Mauritian cynomolgus macaques.

Borsetti A, Ferrantelli F, Maggiorella MT, Sernicola L, Bellino S, Gallinaro A, Farcomeni S, Mee ET, Rose NJ, Cafaro A, Titti F, Ensoli B.

PLoS One. 2014 Apr 2;9(4):e93235. doi: 10.1371/journal.pone.0093235. eCollection 2014.

28.

The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses.

Nicoli F, Finessi V, Sicurella M, Rizzotto L, Gallerani E, Destro F, Cafaro A, Marconi P, Caputo A, Ensoli B, Gavioli R.

PLoS One. 2013 Nov 4;8(11):e77746. doi: 10.1371/journal.pone.0077746. eCollection 2013.

29.

Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16Ink4a.

Cortecchia S, Galanti G, Sgadari C, Costa S, De Lillo M, Caprara L, Barillari G, Monini P, Nannini R, Ensoli B, Bucchi L.

Int J Gynecol Cancer. 2013 Nov;23(9):1663-9. doi: 10.1097/IGC.0b013e3182a80b14.

PMID:
24172101
30.

HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.

Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, Chiozzini C, Ferrantelli F, Cossut MR, Tripiciano A, Nappi F, Longo O, Bellino S, Picconi O, Fanales-Belasio E, Borsetti A, Toschi E, Schiavoni I, Bacigalupo I, Kan E, Sernicola L, Maggiorella MT, Montin K, Porcu M, Leone P, Leone P, Collacchi B, Palladino C, Ridolfi B, Falchi M, Macchia I, Ulmer JB, Buttò S, Sgadari C, Magnani M, Federico MP, Titti F, Banci L, Dallocchio F, Rappuoli R, Ensoli F, Barnett SW, Garaci E, Ensoli B.

PLoS One. 2012;7(11):e48781. doi: 10.1371/journal.pone.0048781. Epub 2012 Nov 13.

31.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011.

Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Armignacco O, Carosi G, Cinque P, d'Arminio Monforte A, Di Perri G, Ensoli B, Floridia M, Galli M, Mastroianni C, Matteelli A, Mazzotta F, Moroni M, Pal G, Puoti M, Puro V, Rizzardini G, Sagnelli E, Vella S, Vullo V, Lazzarin A; Italian HIV Guidelines Working Group.

New Microbiol. 2012 Apr;35(2):113-59. Epub 2012 Mar 31. No abstract available.

32.

Influence of MHC class I and II haplotypes on the experimental infection of Mauritian cynomolgus macaques with SHIVSF162P4cy.

Borsetti A, Maggiorella MT, Sernicola L, Bellino S, Ferrantelli F, Belli R, Fulgenzi D, Mee ET, Rose NJ, Cafaro A, Ensoli B, Titti F.

Tissue Antigens. 2012 Jul;80(1):36-45. doi: 10.1111/j.1399-0039.2012.01875.x. Epub 2012 Apr 12.

PMID:
22494179
33.

Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity.

Barillari G, Iovane A, Bacigalupo I, Palladino C, Bellino S, Leone P, Monini P, Ensoli B.

AIDS. 2012 May 15;26(8):909-19. doi: 10.1097/QAD.0b013e328351f7a5.

PMID:
22313963
34.

Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma.

Sgadari C, Barillari G, Palladino C, Bellino S, Taddeo B, Toschi E, Ensoli B.

Int J Vasc Med. 2011;2011:452729. doi: 10.1155/2011/452729. Epub 2011 Oct 9.

35.

A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses.

Malnati MS, Heltai S, Cosma A, Reitmeir P, Allgayer S, Glashoff RH, Liebrich W, Vardas E, Imami N, Westrop S, Nozza S, Tambussi G, Buttò S, Fanales-Belasio E, Ensoli B, Ensoli F, Tripiciano A, Fortis C, Lusso P, Poli G, Erfle V, Holmes H.

J Immunol Methods. 2012 Jan 31;375(1-2):46-56. doi: 10.1016/j.jim.2011.09.005. Epub 2011 Sep 22.

PMID:
21963950
36.

Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules.

Fraternale A, Paoletti MF, Dominici S, Buondelmonte C, Caputo A, Castaldello A, Tripiciano A, Cafaro A, Palamara AT, Sgarbanti R, Garaci E, Ensoli B, Magnani M.

Vaccine. 2011 Sep 16;29(40):6823-9. doi: 10.1016/j.vaccine.2011.07.101. Epub 2011 Aug 2.

PMID:
21816192
37.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.

Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Carosi G, Cinque P, d'Arminio Monforte A, Di Perri G, Ensoli B, Ferrazzi E, Galli M, Mastroianni C, Matteelli A, Mazzotta F, Moroni M, Palù G, Puoti M, Puro V, Rizzardini G, Sagnelli E, Suter F, Vella S, Lazzarin A; Italian HIV Guidelines Working Group.

New Microbiol. 2011 Apr;34(2):109-46. Epub 2011 Apr 30. No abstract available.

38.

Pharmacological management of Kaposi's sarcoma.

Sgadari C, Bacigalupo I, Barillari G, Ensoli B.

Expert Opin Pharmacother. 2011 Aug;12(11):1669-90. doi: 10.1517/14656566.2011.577066. Epub 2011 Apr 25. Review.

PMID:
21517697
39.

Communication, recruitment and enrolment in the preventative and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein.

Luzi AM, Gallo P, Colucci A, Marcotullio S, Bellino S, Longo O, Ensoli B.

AIDS Care. 2011 Aug;23(8):939-46. doi: 10.1080/09540121.2010.542124. Epub 2011 Jul 7.

PMID:
21390884
40.

A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.

Ferrantelli F, Maggiorella MT, Schiavoni I, Sernicola L, Olivieri E, Farcomeni S, Pavone-Cossut MR, Moretti S, Belli R, Collacchi B, Srivastava IK, Titti F, Cafaro A, Barnett SW, Ensoli B.

Vaccine. 2011 Apr 5;29(16):2918-32. doi: 10.1016/j.vaccine.2011.02.006. Epub 2011 Feb 21.

PMID:
21338681
41.

Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.

Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A, Arancio A, Ariola C, Ruiz Alvarez MJ, Campagna M, Scaramuzzi D, Iori C, Esposito R, Mussini C, Ghinelli F, Sighinolfi L, Palamara G, Latini A, Angarano G, Ladisa N, Soscia F, Mercurio VS, Lazzarin A, Tambussi G, Visintini R, Mazzotta F, Di Pietro M, Galli M, Rusconi S, Carosi G, Torti C, Di Perri G, Bonora S, Ensoli F, Garaci E.

PLoS One. 2010 Nov 11;5(11):e13540. doi: 10.1371/journal.pone.0013540.

42.

Effect of the redox state on HIV-1 tat protein multimerization and cell internalization and trafficking.

Pierleoni R, Menotta M, Antonelli A, Sfara C, Serafini G, Dominici S, Laguardia ME, Salis A, Damonte G, Banci L, Porcu M, Monini P, Ensoli B, Magnani M.

Mol Cell Biochem. 2010 Dec;345(1-2):105-18. doi: 10.1007/s11010-010-0564-9. Epub 2010 Aug 20.

PMID:
20721684
43.

Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases.

Toschi E, Sgadari C, Malavasi L, Bacigalupo I, Chiozzini C, Carlei D, Compagnoni D, Bellino S, Bugarini R, Falchi M, Palladino C, Leone P, Barillari G, Monini P, Ensoli B.

Int J Cancer. 2011 Jan 1;128(1):82-93. doi: 10.1002/ijc.25550.

44.

Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P.

Cafaro A, Bellino S, Titti F, Maggiorella MT, Sernicola L, Wiseman RW, Venzon D, Karl JA, O'Connor D, Monini P, Robert-Guroff M, Ensoli B.

J Virol. 2010 Sep;84(17):8953-8. doi: 10.1128/JVI.00377-10. Epub 2010 Jun 16.

45.

Identification of recent HIV infections and of factors associated with virus acquisition among pregnant women in 2004 and 2006 in Swaziland.

Bernasconi D, Tavoschi L, Regine V, Raimondo M, Gama D, Sulgencio L, Almaviva M, Galli C, Ensoli B, Suligoi B, Sukati H, Buttò S.

J Clin Virol. 2010 Jul;48(3):180-3. doi: 10.1016/j.jcv.2010.04.010.

PMID:
20537582
46.

Spindle cells from AIDS-associated Kaposi's sarcoma lesions express telomerase activity that is enhanced by Kaposi's sarcoma progression factors.

Barillari G, Franzese O, Comandini A, Bonmassar E, Ensoli B.

Oncol Rep. 2010 Jul;24(1):219-23.

PMID:
20514465
47.

Characterization of HIV type 1 genetic diversity among South African participants enrolled in the AIDS Vaccine Integrated Project (AVIP) study.

Papathanasopoulos MA, Vardas E, Wallis C, Glashoff R, Buttó S, Poli G, Malnati M, Clerici M, Ensoli B.

AIDS Res Hum Retroviruses. 2010 Jun;26(6):705-9. doi: 10.1089/aid.2009.0281.

PMID:
20509797
48.

Spindle cells from acquired immune deficiency syndrome-associated Kaposi's sarcoma lesions express telomerase activity directly relating to the RNA levels of fibroblast growth factor-2.

Barillari G, Franzese O, Iovane A, Ensoli B.

Int J Cancer. 2010 Nov 15;127(10):2487-9. doi: 10.1002/ijc.25268. No abstract available.

49.

Fibroblast growth factor-2 transiently activates the p53 oncosuppressor protein in human primary vascular smooth muscle cells: implications for atherogenesis.

Barillari G, Iovane A, Bonuglia M, Albonici L, Garofano P, Di Campli E, Falchi M, Condò I, Manzari V, Ensoli B.

Atherosclerosis. 2010 Jun;210(2):400-6. doi: 10.1016/j.atherosclerosis.2010.01.006. Epub 2010 Jan 21.

PMID:
20122687
50.

Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS.

Cafaro A, Macchia I, Maggiorella MT, Titti F, Ensoli B.

Adv Exp Med Biol. 2009;655:189-242. doi: 10.1007/978-1-4419-1132-2_14. Review.

PMID:
20047043

Supplemental Content

Loading ...
Support Center